Table 1

Demographic, clinical, MRI, and network metrics

HC (n=51)Patients with MS (n=122)RRMS (n=58)PPMS (n=28)SPMS (n=36)
 Age, years41±1348±1142±1052±953±7
 Gender (M/F)25/2636/8618/4010/188/28
 Disease duration, years15±1011±814±722±10
 % (n) patients of DMTs58 (67)84 (48)13 (3)47 (16)
 % (n) patients who relapsed in the previous 2 years51 (38)68 (32)0 (0)24 (6)
Clinical scores
 EDSS, median5.5 (0–8.5)2 (0–7)6 (3–8)6.5 (4–8.5)
MRI metrics
 NABV (cm3 ) 1158±1021042±1201070±1231060±122984±93
 GM (cm3)679±57625±65641±64632±67593±52
 CGM (cm3)640±54591±61606±61597±65561±50
 DGM (cm3)39.00±3.3934.18±4.0234.86±4.0935.41±3.5032.12±3.54
 NAWM (cm3)480±49418±59429±62429±60391±45
 LL (mL)14.37±15.9212.78±15.7216.56±19.8315.23±12.73
Network metrics
 Edge density, (%)92.6±2.790.6±3.290.8±3.390.5±3.090.3±3.0
 Global efficiency3881±1213783±1753827±1373763±1963729±199
 Mean local efficiency3975±1393889±2003934±1603868±2203831±229
 Mean clustering coefficient247±9.2223±18.3227±17.2224±20.5217±16.8
  • CGM, cortical grey matter; DGM, deep grey matter; DMT, disease-modifying treatment; EDSS, Expanded Disability Status Scale; GM, grey matter; HC, healthy controls; LL, lesion load; MS, multiple sclerosis; NABV, normal-appearing brain volume; NAWM, normal-appearing white matter; PPMS, primary progressive MS; RRMS, relapsing remitting MS; SDMT, Symbol Digit Modalities Test; SPMS, secondary progressive MS.